1Nonclinical features of small nucleic acid drugs and the pharmacology and toxicology evaluation strategyWANG Heng, LI Hua, WANG Xi-jie, QIU Yun-liang, TANG Na-ping, HUANG Fang-hua, CHANG Yan1137-11452Analysis of regulatory measures in response to"N-nitrosodimethylamine impurity"pharmaceuticals incidentsWANG Li-jie, ZHAI Tie-wei1146-11503The inspiration to new drug research and development in China from the drug patent time extended in KoreaGU Dong-lei, PAN Xiao-mei, ZHENG Yong-nan, JIAN Yu-cong, XING Xing1151-11564Validation of method for assay of residual protein A in antibody drugsFU Zhi-hao, ZHONG Xin, XU Gang-ling, YU Chuan-fei, WANG Lan1169-11775Bioequivalence study of epinastine hydrochloride tablets after single dose administration in healthy volunteersYANG Ke-xu, JING Shan, GAO Kun, LI Xing-yu, TAN Li, LIU Wen-fang, LU Chun-yan, LIN Yang1178-11826Consensus on the risk evaluation and quality management during clinical trials of anti-cancer drugs (2021 version)ZHANG Ling1188-11947Study on the current situation and influencing factors of tumor patients participating in drug clinical trialsXING Shu-jun, CHEN He-fang, HU Meng-die, WANG Shu-hang, WU Da-wei, YU Ling1201-12088Effect of corilagin on TLR3 pathway in mice with viral myocarditisZHU Zhi-de, LU Jian-qi, YANG Rui-xia, PAN Chao-xin, WANG Qing-gao, HAN Jing-bo, PANG Yan, CHEN Wen-peng, JIANG Zhi-xiong1209-12149Study on method for detection of bacterial endotoxin in recombinant cholera toxin B subunit protein derived from Escherichia coliHE Hua-hong, WANG Hua-qian, LI Wei1230-123510Adverse reactions of spleen polypeptide injection in 137 cases in Jiangsu province during 2011-2021ZHANG Yan-fen1236-1240